AstraZeneca has allocated $3.5billion to expand its US manufacturing and research footprint by the end of 2026. The funding ...

MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the ...

Cambridge: AstraZeneca has announced $3.5 billion of capital investment in the United States focused on expanding the Company ...

In a statement, the office of the Dominican prime minister said President of the Commonwealth of Dominica Sylvanie Burton ...

Nathalie Fuentes shared her experience of landing a unicorn position in a pharmaceutical company after a postdoctoral ...

A woman whose cancer has spread to her bones, back, pelvis and neck but has been denied a life-extending drug because she ...

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

The UK must harness AI 's transformative power to 'revolutionise the healthcare system' and slash cancer deaths, Lord Darzi ...

Bernstein analyst Justin Smith maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of p18,000.00. Justin Smith has given his Buy rating due to a combination of ...